Patrick Merle

TL;DR: Atezolizumab monotherapy in relapsed SCLC failed to show significant efficacy and no unexpected safety concerns were observed.

TL;DR: Assessment of plasma cfDNA concentration in a large series of patients with NSCLC and treated with a standard chemotherapy regimen found total concentration of cfDNA does not appear to predict chemotherapy response, but increased baseline concentration ofcfDNA was an independent prognostic factor.

TL;DR: The primary end point of the trial was met, demonstrating the feasibility of a national biology-driven trial in the adjuvant NSCLC setting, and the phase III part was canceled because of the unreliability of the ERCC1 immunohistochemical readouts.

TL;DR: This study highlights the complementarity of different diagnostic approaches and variability of results between OncoBEAM™-RAS-CRC and NGS assays and provides a larger breadth of coverage of the major targetable alterations of 56 genes in one run.

TL;DR: Findings provide the first evidence that exposure to a G4 ligand radiosensitizes human glioblastoma cells and suggest the prospect of future therapeutic applications.